Claims

1. A compound of Formula (I):



(I)

or a stereoisomer, a tautomer, a solvate or a pharmaceutically acceptable salt thereof, wherein:

L_1 is independently L_4-O or O-L_4;

L_2 is independently a hydrocarbon linker substituted with 0-2 R^c, a hydrocarbon-heteroatom linker substituted with 0-2 R^c, or -$(CH_2)_{1-2}$-(C_{3-4} cycloalkyl substituted with 0-2 R^c)-$(CH_2)_{0-1}$-; wherein said hydrocarbon linker has one to six carbon atoms and may be straight or branched, saturated or unsaturated; and said hydrocarbon-heteroatom linker has one to four carbon atoms and one group selected from O, -CO-, S, -SO-, -SO_2-, NH, N(C_{1-4} alkyl), -CONH-, and -NHCO-;

L_4 is independently a bond or a hydrocarbon linker; wherein said hydrocarbon linker has one to four carbon atoms and may be straight or branched;

R^1 is independently selected from: C_{6-10} carbocycle and a 5- to 10-membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, NR^b, O, and $S(O)_p$; wherein said carbocycle and heterocycle are substituted with 0-4 R^3 and 0-1 R^4;

R^2 independently selected from: OH, CO_2H, CO_2(C_{1-4} alkyl), $CONR^eNR^f$, and -$CONHSO_2R^f$;

R^3, at each occurrence, is independently selected from: halogen, C_{1-6} alkyl, C_{1-4} alkoxy, C_{1-4} alkylthio, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, C_{1-4} haloalkylthio, and NO_2;

R^4 is independently -L_3-R^5;

L_3 is independently selected from: a bond, O, and C(=O);

R^5 is independently selected from: phenyl and a 5- to 6-membered heteroaryl comprising carbon atoms and 1-4 heteroatoms selected from N, NR^b, O, and $S(O)_p$;

wherein each ring moiety is substituted with 0-2 R^a;

R^a, at each occurrence, is independently selected from: halogen, C_{1-4} alkyl, C_{1-4} alkoxy, and C_{1-4} haloalkyl;

R^b, at each occurrence, is independently selected from: H, C_{1-4} alkyl, and $-(CH_2)_{0-2}$-(phenyl substituted with 0-3 R^d);

R^c, at each occurrence, is independently selected from: =O, halogen, OH, C_{1-4} alkyl, C_{1-4} haloalkyl, and C_{1-4} alkoxy;

R^d, at each occurrence, is independently selected from: halogen, C_{1-4} alkyl, C_{1-4} alkoxy, and C_{1-4} haloalkyl;

R^e, at each occurrence, is independently selected from: H and C_{1-4} alkyl;

R^f, at each occurrence, is independently selected from: H, C_{1-4} alkyl, $-(CH_2)_{0-2}$-phenyl, and C_{3-6} cycloalkyl substituted with 1-2 OH;

R^e and R^f may be combined with the nitrogen atom to which they are attached to form a 4- to 6-membered heterocyclic ring comprising carbon atoms and 1 additional heteroatom selected from N, NR^b, O, and S; wherein said heterocycle is substituted with and 0-1 OH; and

p is, independently at each occurrence, selected from 0, 1, and 2.

2. A compound according to claim 1, wherein:

L_1 is independently L_4-O;

L_2 is independently a hydrocarbon linker substituted with 0-1 R^c, a hydrocarbon-heteroatom linker substituted with 0-1 R^c, or $-(CH_2)_{1-2}$-(C_{3-4} cycloalkyl substituted with 0-1 R^c)-$(CH_2)_{0-1}$-; wherein said hydrocarbon linker has one to six carbon atoms and may be straight or branched, saturated or unsaturated; and said hydrocarbon-heteroatom linker has one to four carbon atoms and one group selected from O and S;

R^1 is independently selected from: phenyl, indanyl, naphthyl, and a 5- to 10-membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, NR^b, O, and $S(O)_p$; wherein each ring moiety substituted with 0-4 R^3 and 0-1 R^4; and

R^4 is independently selected from: thienyl, oxadiazolyl, and -L_3-phenyl; wherein each ring moiety is substituted with 0-2 R^a.

3. A compound according to claim 1 or claim 2, wherein the compound is of Formula (II):



(II)

or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein:

L_2 is independently a hydrocarbon linker a hydrocarbon-heteroatom linker, or -$(CH_2)_{1-2}$-(cyclopropyl substituted with 0-1 R^c)-$(CH_2)_{0-1}$-; wherein said hydrocarbon linker has one to five carbon atoms and may be straight or branched, saturated or unsaturated; and said hydrocarbon-heteroatom linker has one to three carbon atoms and one O;

L_4 is independently selected from: a bond, CH_2 and CH(C_{1-4} alkyl);

R^1 is independently selected from: , and a ring moiety substituted with 0-2 R^3 and selected from the group consisting of thienyl, , isoxazolyl, pyrimidinyl, indanyl, naphthyl, benzothiophenyl, and ;

R^3, at each occurrence, is independently selected from: NO_2, halogen, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkylthio, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, and C_{1-4} haloalkylthio;

R^4 is independently selected from: thienyl, oxadiazolyl, and -L_3-phenyl; wherein each ring moiety is substituted with 0-2 R^a;

L_3 is independently selected from: a bond, O, and C(=O);

R^a, at each occurrence, is independently selected from: halogen and C_{1-4} alkyl; and

R^b is independently phenyl substituted with 0-2 halo.

4. A compound according to claims 1 to 3, wherein:

L_2 is independently selected from: CH_2OCH_2, OCH_2CH_2, $CH_2CH_2CH_2$, $CH_2CH(C_{1-2}$ alkyl$)CH_2$, $CH_2CH_2CH(C_{1-2}$ alkyl$)$, $CH_2CH{=}CH$, and ;

R^1-L_4- is independently selected from:



, and ;

R^3, at each occurrence, is independently selected from: halogen, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkylthio, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, and C_{1-4} haloalkylthio;

R^4 is independently selected from: thienyl and -L_3-(phenyl substituted with 0-2 halo); and

L_3 is independently selected from: a bond, O, and C(=O).

5. A compound according to claims 1 to 4, wherein:

L_2 is independently selected from the group consisting of CH_2OCH_2, OCH_2CH_2, $CH_2CH_2CH_2$, $CH_2CH(Me)CH_2$, $CH_2CH_2CH(Me)$, $CH_2CH{=}CH$, and ; and

R^1-L_4- is independently selected from:



, and .

6. A compound according to claims 1 to 5, wherein:

L_2 is independently selected from: OCH_2CH_2, $CH_2CH_2CH_2$, and ;

and

R^1-L_4- is independently selected from:



, and .

7. A compound according to claims 1 to 6, wherein:

R^1-L_4- is independently selected from:



, and .

8. A compound according to claim 1, wherein the compound is selected from 4-(4-((1-(4-Chlorophenyl)-3-methyl-1H-pyrazol-5-yl)methoxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(2-fluoro-5-methoxybenzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-((5-chloro-2,2-dimethyl-2,3-dihydrobenzofuran-7-yl)methoxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(3,5-dichlorobenzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(5-chloro-2-isopropoxybenzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(3-chloro-5-phenoxybenzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(3-methyl-5-(trifluoromethoxy)benzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(1-(3-(trifluoromethyl)phenyl)ethoxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(4,6-dichloro-2,3-dihydro-1H-inden-1-yloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(2-chlorobenzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(3,4-dichlorobenzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(3-fluoro-4-methylbenzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(4-fluoro-3-methylbenzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(2-phenoxybenzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(3-phenoxybenzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(3-(2-fluorophenoxy)benzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(3-(4-fluorophenoxy)benzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(3-chloro-5-(trifluoromethoxy)benzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(5-chloro-2-(trifluoromethoxy)benzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(2-(trifluoromethoxy)benzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(3,5-dimethoxybenzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(3-chloro-5-fluorobenzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(3-chlorobenzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(4-chlorobenzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(3-fluoro-5-(trifluoromethyl)benzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(3-(trifluoromethoxy)benzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(3-fluoro-5-methoxybenzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(3-fluoro-5-(trifluoromethoxy)benzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(2-methoxy-5(trifluoromethoxy)benzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-((5-

chlorobenzo[b]thiophen-3-yl)methoxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(3-chloro-5-methoxybenzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(3-(4-chlorophenoxy)benzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(2-fluoro-5-(trifluoromethoxy)benzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(3-fluoro-5-phenoxybenzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(3-fluoro-5-isopropoxybenzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(2-isopropoxybenzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(3-(5-methyl-1,2,4-oxadiazol-3-yl)benzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(3-isopropoxybenzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(3-benzoyloxybenzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(4-chloro-2-methoxybenzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(2,4-dichlorobenzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(2-fluoro-4-methoxybenzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(4-methoxy-2-(trifluoromethyl)benzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-5-fluoro-2-(trifluoromethoxy)benzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(3-chloro-2-fluorobenzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(2-fluoro-3-(trifluoromethyl)benzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(2,3,6-trifluorobenzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(biphenyl-2-ylmethoxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(2-(trifluoromethylthio)benzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(3-(trifluoromethylthio)benzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(2-chloro-5-nitrobenzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(5-chloro-2-fluorobenzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(2,3-difluorobenzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-((2-bromothiophen-3-yl)methoxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(2-chloro-3-(trifluoromethyl)benzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(2-chloro-3,6-difluorobenzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(biphenyl-3-ylmethoxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(4-phenoxybenzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(2,3,6-trichlorobenzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(5-bromo-2-methoxybenzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(3-(thiophen-2-yl)benzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(5-bromo-2-

methylbenzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(2-chloro-5-(trifluoromethyl)benzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(2-(trifluoromethyl)benzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-(-(trifluoromethyl)benzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, methyl 4-(4-((4-fluoro-4'-methy1-[1,1'-bipheny1]-2-yl)methoxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 4-(4-((2-(methylthio)pyrimidin-4-yl)methoxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 2-Methyl-4-(4-(2-phenoxybenzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 3-Methyl-4-(4-(3-phenoxybenzyloxy)bicyclo[2.2.1]heptan-1-yl)butanoic acid, 3-(4-((5-Chloro-2,2-dimethyl-2,3-dihydobenzofuran-7-yl)methoxy)bicyclo[2.2.1]heptan-1-yl)propan-1-ol, 3-(4-((5-Chloro-2,2-dimethyl-2,3-dihydobenzofuran-7-yl)methoxy)bicyclo[2.2.1]heptan-1-yl)propanoic acid, 2-((4-(2-Phenoxybenzyloxy)bicyclo[2.2.1]heptan-1-yl)methoxy)acetic acid, 2-((4-(3-fluoro-5-Phenoxybenzyloxy)bicyclo[2.2.1]heptan-1-yl)methoxy)acetic acid, 2-((4-(3-Phenoxybenzyloxy)bicyclo[2.2.1]heptan-1-yl)methoxy)acetic acid, 2-((4-(3-fluoro-5-(4-fluorophenoxy)benzyloxy)bicyclo[2.2.1]heptan-1-yl)methoxy)acetic acid, 2-((4-(1-(3-fluoro-5-(4-fluorophenoxy)phenyl)ethoxy)bicyclo[2.2.1]heptan-1-yl)methoxy)acetic acid, 2-((4-((5-chloro-2,2-dimethyl-2,3-dihydrobenzofuran-7-yl)methoxy)bicyclo[2.2.1]heptan-1-yl)methoxy)acetic acid, 2-((4-((3-chloro-5-(trifluoromethoxy)benzyloxy)bicyclo[2.2.1]heptan-1-yl)methoxy)acetic acid, 3-(4-(3-Fluoro-5-phenoxybenzyloxy)bicyclo[2.2.1]heptan-1-yloxy)methoxy)propanoic acid, 3-(4-(2-phenoxybenzyloxy)bicyclo[2.2.1]heptan-1-yloxy)methoxy)propanoic acid, 3-(4-(3-fluoro-5-(4-fluorophenoxy)benzyloxy)bicyclo[2.2.1]heptan-1-yloxy))propanoic acid, 3-(4-(1-(3-fluoro-5-(4-fluorophenoxy)phenyl)ethoxy)bicyclo[2.2.1]heptan-heptan-1-yloxy)propanoic acid, 4-(4-(5-Fluoro-2-phenoxybenzyloxy)bicyclo[2.2.1]heptan-1-yl)N-(methylsulfonyl) butanamide, N-methyl-4-(4-((3-phenoybenzyl)oxy)bicyclo[2.2.1]heptan-1-yl)butanamide, 1-(3-Hydroxyazetidin-1-yl)-4-(4-((3-phenoxybenzyl)oxy)bicyclo[2.2.1]heptan-1-yl)butanl-one, 3-(4-(2-Phenoxyphenethoxy)bicyclo[2.2.1]heptan-1-yl)propanoic acid, 3-(4-(2-(naphthalen-1-yl)ethoxy)bicyclo[2.2.1]heptan-1-yl)propanoic acid, 3-(4-(3-phenoxyphenethoxy)bicyclo[2.2.1]heptan-1-yl)propanoic acid, 3-((1S,4R)-4-(2-fluoro-5-(trifluoromethoxy)phenethoxy)bicyclo[2.2.1]heptan-1-yl)propanoic acid, 3-(4-((3-fluoro-5-phenoxybenzyl)oxy)bicyclo[2.2.1]heptan-1-yl)propanoic acid, 2-((4-((3-Fluoro-5-phenoxybenzyl)oxy)bicyclo[2.2.1]heptan-1-yl)methyl)cyclopropanecarboxylic acid, (E)-

4-(4-((3-Phenoxybenzyl)oxy)bicyclo[2.2.1]heptan-1-yl)but-2-enoic acid, 2-((4-((3-Phenoxybenzyl)oxy)bicyclo[2.2.1]heptan-1-yl)methyl)cyclopropanecarboxylic acid, N-(2-Amino-2-oxoethyl)-4-(4-((3-fluoro-5-phenoxybenzyl)oxy)bicyclo[2.2.1]heptan-1-yl)butanamide, 2-(4-((3-Fluoro-5-phenoxybenzyl)oxy)bicyclo[2.2.1]heptan-1-yl)ethanol, 2-(2-(4-((3-Fluoro-5-phenoxybenzyl)oxy)bicyclo[2.2.1]heptan-1-yl)ethoxy)acetic acid or a stereoisomer, a tautomer, a solvate or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a compound of any one of claims 1 to 8, or a stereoisomer, a tautomer, a solvate or a pharmaceutically acceptable salt thereof.

10. The pharmaceutical composition according to claim 9, further comprising one or more other suitable therapeutic agents useful in the treatment of the aforementioned disorders including: anti-diabetic agents, anti-hyperglycemic agents, anti-hyperinsulinemic agents, anti-retinopathic agents, anti-neuropathic agents, anti-nephropathic agents, anti-atherosclerotic agents, anti-ischemic agents, anti-hypertensive agents, anti-obesity agents, anti-dyslipidemic agents, anti-hyperlipidemic agents, anti-hypertriglyceridemic agents, anti-hypercholesterolemic agents, anti-pancreatitis agents, lipid lowering agents, anorectic agents and appetite suppressants.

11. The pharmaceutical composition according to claim 10, further comprising one or more other suitable therapeutic agents selected from: a dipeptidyl peptidase-IV inhibitor, a sodium-glucose transporter-2 inhibitor and a 11b-HSD-1 inhibitor.

12. The compound of any one of claims 1 to 8, or a stereoisomer, a tautomer, a solvate or a pharmaceutically acceptable salt thereof for use in therapy.

13. The compound of any one of claims 1 to 8, or a stereoisomer, a tautomer, a solvate or a pharmaceutically acceptable salt thereof for use in treating diabetes, hyperglycemia, impaired glucose tolerance, gestational diabetes, insulin resistance, hyperinsulinemia, retinopathy, neuropathy, nephropathy, diabetic kidney disease, acute

kidney injury, cardiorenal syndrome, delayed wound healing, atherosclerosis and its sequelae, abnormal heart function, congestive heart failure, myocardial ischemia, stroke, Metabolic Syndrome, hypertension, obesity, fatty liver disease, dislipidemia, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low high-density lipoprotein (HDL), high low-density lipoprotein (LDL), lipid disorders and liver diseases such as NASH (Non-Alcoholic SteatoHepatitis), NAFLD (Non-Alcoholic Fatty Liver Disease) and liver cirrhosis.

14. A compound for use according to claim 13, wherein the compound of any one of claims 1 to 8 is used simultaneously, separately or sequentially with one or more additional therapeutic agents.